Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - IMS Health Holdings, Inc.a51062828ex99_1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)
March 17, 2015

IMS Health Holdings, Inc.
(Exact name of registrant as specified in charter)

Delaware   001-36381   27-1335689

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

83 Wooster Heights Road
Danbury, CT 06810
(Address of Principal Executive Offices, including Zip Code)

(203) 448-4600
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement.

     On March 17, 2015, IMS Health Incorporated (the “Issuer”), a wholly-owned subsidiary of IMS Health Holdings, Inc. (“IMS Health”), entered into a purchase agreement with the representatives of certain initial purchasers, relating to the issuance and sale of €275 million in gross proceeds of the Issuer’s Senior Notes due 2023 bearing interest at a rate of 4.125%. The net proceeds from the notes offering will be used to fund a portion of the purchase price for IMS Health’s previously announced proposed acquisition of certain customer relationship management and strategic data businesses of Cegedim, SA and for related fees and expenses. The consummation of the notes offering is subject to market and other conditions.

Item 8.01 Other Events.

     On March 19, 2015, IMS Health issued a press release announcing the pricing of the notes offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01  Financial Statements and Exhibits.

        (d) Exhibits

99.1      Press release dated March 19, 2015.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   

IMS Health Holdings, Inc.

 
By: /s/ Ronald E. Bruehlman
Name: Ronald E. Bruehlman
Title: Senior Vice President &

Chief Financial Officer

Date: March 19, 2015